Telemedinsk udvikling
|
|
|
- Letitia Hodge
- 8 years ago
- Views:
Transcription
1 F A C UL T Y O F HE AL T H A ND ME D I C A L S C I E N C E S U N I V E R S I T Y O F C O P E N H A G E N Telemedinsk udvikling Motivational Interviewing Sygeplejerskens rolle - i centrum af ehealth Fagligt Selskab for Gastroenterologiske Sygeplejersker Professor Pia Munkholm & IBD specialist nurse Dorte Marker University of Copenhagen
2
3 Motivational Interviewing Network of Trainers William R. Miller and Stephen Rollnick in Virginia, USA (2008) Interest: to improve the quality and effectiveness of counseling & consultations with clients about behavior change. Research focus on: Good practice in efforts to promote change and behaviour change among patients, clients and the practitioners who serve them(1998) Motivation is not seen as static but as dynamic. It is purposeful, intentional, and positive-directed toward the best interest of self (1983) Stepen Rollnick, Professor of Healthcare Communication at Cardiff University, clinical psychologist
4 DEEP-Danish Ehealth & Epidemiology group UC SCCAI 43/55% Agressive 20% Agressive 9% agressive: relapse every year 3/1% FC Moderate 36% Moderate 70% Moderate: Half of the years in inactive stage 19/6% Indolent 44% Mild 21% Mild-indolent: Inactive since diagnosis or the majority of the years 32/37% TIBS= SCCAI + FC Crohns disease/ulcerative colitis 8 years Crohns disease/ulcerative colitis 10 years Deep remission SCCAI <1 FC<100mg/kg P Munkholm SJG 1995, E Langholz Gastro 1994(UC) IC Solbjerg. CGH 2007(CD); SJG 2009(UC) Pedersen N. IBD 2014, DMJ 2015, Elkjaer M. DMJ 2012
5 Study methods: assessment of damage Extent x Severity
6 Digestive Damage Progression of digestive disease damage (Lémann score) and inflammatory activity Stricture Fistula/abscess Surgery Stricture Inflammatory Activity (CDAI, CDEIS, CRP) Disease onset Pre-clinical Diagnosis Early disease Clinical CDAI: Crohn's Disease Activity Index; CDEIS : Crohn s Disease Endoscopic Index of Severity; CRP: C-Reactive Protein Pariente B et al. Inflamm Bowel Dis 2011;17(6):
7 Download for free
8 Web-epidemiology & web-applications EPIDEMIOLOGIC web-databases 1. Povl Riis , FU DCCD; Danish Crohn Colitis Database EpiCom, European Database , 32 centre, web epidemiological database 4. CSO, MD, Ph.D Johan Burisch ehealth web-applications any 5asa) 2 (CD IFX) 4 meza) children) any) Elkjaer M. EJGH 2009
9 Why ehealth? SMART phone Fecal Calprotectin Homemoni toring Disease activity Selfinitiate Compliance Adherence
10 ehealth adjuvant & achivement Goal Mucosal healing Change of natural disease course Adherence/compliance QoL PRO personal reported out-come Recognition of a relapse Self-initiate 5asa high dose for 1 month Shorten time to remission Acheivements 2014 IBD, IBS & IBS-IBD Mucosal healing by FC, fecal calprotectin NDC-yet to be proven long-term Adherence/compliance QoL PRO by web-app solution Recognition of a relapse Self-initiate 5asa high dose for 1 month Shorten time to remission Elkjaer M. Dan Med J 2012, Pedersen N. Dan Med J 2013
11 TRAFIC LIGHT WEB-APPLICATION Elkjaer M. APT 2009 Self-initiated MMX Mezavant 12 weeks Pedersen N. IBD 2014, Elkjaer M. EJGH 2010
12 Can we during partner ship deminish disease activity over time? Change of the natural disease score MD Standard care WEB-Doctor ibd nurse/patient Conventionel Course ehealth web-app
13 ehealth: diminish inflammation burden? Disease course: Standard care ehealth web-app Treatment begin Days(range) 0 78 days (range (46-108) 0 17 days 0 10 days 0 7 days (range 10-21) MD WEB DOCTOR/PATIENT/NURSE Elkjaer M. GUT 2010
14 Clinical Integrated Home Monitoring Home-monitoring, screening 1 -symptomscore -fecal calprotectin CIH Patient contact/ IBD nurse IBD Call center Standard therapy Hospital visit with monitoring at outpatient clinic -symptomscore -feces calprotectin 0 6 month Vinding KK, Marker D in progress
15 egastro, CIH: Lead time bias 1 ehealth influencing time, disease course & disease damage WEB group n=125 pts Home monitoring: symptomscore + Feces Relapse confirmed by trafic light scoring Lead time Crohn & Colitis ulcerosa randomised Expected remission-time Standard care, no screening CONTROL n=125 pts Relapse bleeding/pain Relapse confirmed only by symprtomscore at out-patient clinic Consultation & treatment Expected remission-time Inactive disease No symptoms/bleeding/pain
16 ehealth: UC 1 year any 5-asa 2 Elkjaer M. GUT & Dan Med J 2012
17 ehealth: UC non-adherent to 5-asa 3 QoL Fecal Calprotectin SCCAI Pedersen N. IBD 2014 & Dan Med J 2015
18 ehealth: Crohns infliximab 1 year 4 QoL Inflammation Burden Pedersen N. APT 2012
19 5 ehealth: IBS IBS lowfodmap, Lactobac Rhamnosus, Danish nutrition Pedersen N. WJG 2014 & 2015
20 ehealth: IBS-IBD 6 Pedersen N. WJG 2015, GUT 2015, Dan Med J 2015
21 ehealth: IBS-IBD decreasing of FODMAPS (gram) 6 Pedersen N. WJG 2015, GUT 2015, Dan Med J 2015
22 Future ehealth ehealth CIH-Clinical Integrated Homemonitoring Standard care egastro egravid u- og kompliceret ekol ediabetes ehealth Homemonitoring & individualized therapy Patient empowerment compliance Self-initiated treatment 5asa Treat to target-mucosa healing Health platform EPIC Patient access Staff access
23 Tak Invitation: Phd forsvar PANUM 16/1-15, kl 14 Dorte Marker, forskningssygeplejerske Hanne Fuglsang, bioanalytiker Tina Sørensen, bioanalytiker Tine Thokilgaard, stud med Louise Maagaard, stud med Line Molzen, stud med Henriette Elsberg, stud med Sara Al-Nawas, stud med Zsuzsanna Vegh, MD (Hungary) Johan Burisch, ph.d., læge Kristoffer Kofod Vinding, læge, ph.d. stud. Katrine Carlsen, læge, Ph.d. stud. Natalia Pedersen, overlæge, Phd Pia Munkholm, Professor
Decision systems in quality registries
Decision systems in quality registries Stockholm Dec 9 th, 2014 Jonas Halfvarson, MD, PhD Dept of Gastronterology, Faculty of Medicine and Health, Örebro University 1 Quality registries for chronic diseases
Evidence of Crohn s Disease. Case Presentation
Witt Wait to Treat tutiled Until Endoscopic Evidence of Crohn s Disease Raymond Cross, MD, MS, AGAF Associate Professor of Medicine Director, IBD Program University of Maryland School of Medicine Co-Director,
How To Treat Colitis With A Combination Of Antibiotics
18 Simposio annuale ELAS-LIGAND LIGAND ASSAY 2012 LE MALATTIE INFIAMMATORIE INTESTINALI Aspetti Fisiopatologici e Clinici Giovanni Maconi Cattedra di Gastroenterologia Dipartimento di Scienze Biomediche
Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago
Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms Stephen B. Hanauer, M.D. University of Chicago Treatment Goals c.2008 Induce and maintain response/remission Prevent complications Disease
Measuring severity of disease and defining treatment benefit using the Simple Endoscopic Activity Score (SES-CD)
Measuring severity of disease and defining treatment benefit using the Simple Endoscopic Activity Score (SES-CD) Jean-Frederic COLOMBEL Icahn Medical School at Mount Sinai, New York J-F Colombel has served
What are the Unmet Needs in the Management of IBD?
23/6/214 What are the Unmet Needs in the Management of IBD? Shane Devlin, MD, FRCPC Inflammatory Bowel Disease Group The University of Calgary Some Real Cases: #1 32 yo male with pan UC. Grumbling phenotype
Proposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine
Proposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine Contents Mission... 1 Background... 2 Services and Programs... 2 Clinical Care... 2 IBD Specialists...
Choosing Outcome Measures in Pediatric IBD. Anne M Griffiths, MD Hospital for Sick Children University of Toronto Toronto, Canada
Choosing Outcome Measures in Pediatric IBD Anne M Griffiths, MD Hospital for Sick Children University of Toronto Toronto, Canada Disclosures The content of this presentation reflect my personal opinions
11/10/2014. New Treatments in IBD: When, Whom and How. Background. Background. Options. Disease Assessment. What is the evidence?
New Treatments in IBD: When, Whom and How. Background Options Disease Assessment What is the evidence? Kofi Clarke MD, FACP,FRCP (Lond) Clinical Associate Professor, Chief, Gastroenterology, Hepatology
Crohn s and Colitis Center
Crohn s and Colitis Center Dedicated to caring for patients with inflammatory bowel disease Crohn s disease and ulcerative colitis. The Crohn s and Colitis Center is the only center in New England exclusively
Research in IBD at University of Colorado Denver
Research in IBD at University of Colorado Denver Blair Fennimore, MD Assistant Professor of Medicine Division of Gastroenterology and Hepatology UCH Crohn s and Colitis Center Mucosal Inflammation Program
improving lives through collaborative medicine
improving lives through collaborative medicine ImproveCareNow is a collaborative chronic care network of 77 care centers in 35 states and the District of Columbia and England, where clinicians, researchers,
TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER
Press information for journalists only TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER Why treat IBD? IBD describes a range of chronic diseases of the gastrointestinal system, encompassing Ulcerative
Leukapheresis for inflammatory bowel disease
Issue date: June 2005 Leukapheresis for inflammatory bowel disease Understanding NICE guidance information for people considering the procedure, and for the public Information about NICE Interventional
Understanding Colitis and Crohn s Disease
Improving life for people affected by Colitis and Crohn s Disease Understanding Colitis and Crohn s Disease 1 Understanding Colitis and Crohn s Disease Understanding Ulcerative Colitis and Crohn s Disease...
Probiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
Focus Biobank Inflammatory Bowel Disease
Focus Biobank Inflammatory Bowel Disease University Hospitals Leuven KU Leuven Isabelle Cleynen, PhD Inflammatory Bowel Disease Crohn s disease (CD) Entire GI tract Transmural Fistulas and/or strictures
Endoscopy is an important diagnostic and therapeutic
ORIGINAL ARTICLE Appropriateness and Diagnostic Yield of Colonoscopy in the Management of Patients with Ulcerative Colitis: A Prospective Study in an Open Access Endoscopy Service Gianpiero Manes, MD,
Terapia con farmaci biologici e non nella. Sandro Ardizzone. Azienda Ospedaliera Fatebenefratelli e. Ospedale di Rilievo Nazionale Milan
Terapia con farmaci biologici e non nella Colite Ulcerosa Severa/Refrattaria Sandro Ardizzone Gastrointestinal Unit Azienda Ospedaliera Fatebenefratelli e Oftalmico Ospedale di Rilievo Nazionale Milan
Briefing Document. Food and Drug Administration. Center for Drug Evaluation and Research
Briefing Document Food and Drug Administration Center for Drug Evaluation and Research Meeting: Joint Meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC) and the Drug Safety and Risk Management
The Oxford IBD Service
Gastroenterology Unit, John Radcliffe Hospital The Oxford IBD Service Information for patients Information for patients 1 The Oxford Inflammatory Bowel Disease (IBD) Service Consultant Gastroenterologists
How long will it take to work? You may begin to feel better within a few days or it may take up to six weeks after your first treatment session.
Crohn's and Colitis UK Drug Treatment Information Improving life for people affected by inflammatory bowel diseases Infliximab This information leaflet aims to answer common questions you may have if you
Inflammatory Bowel Disease
Inflammatory Bowel Disease Laboratory Support of Diagnosis and Management CLINICAL BACKGROUND Inflammatory bowel disease (IBD), which includes Crohn disease (CD) and ulcerative colitis (UC), is characterized
Medical Therapy for IBD
CHILDREN S DIGESTIVE HEALTH & NUTRITION FOUNDATION NORTH AMERICAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION Medical Therapy for IBD I. INTRODUCTION The treatment of Crohn s disease
Secure Messaging Evidence Table
APPENDIX E. Evidence Tables Secure Messaging Evidence Table Health Outcomes Simon, 2011 9 RCT; N=208 patients; 04/09-10/09 Elkjaer, 2010 1 Zhou, 2010 2 Harris, 2009 3 Ralston, 2009 6 Tuil, 2007 4 RCT;
Change in Incidence of Crohn s Disease and Ulcerative Colitis in Denmark. A Study Based on the National Registry of Patients, 1981 1992
International Journal of Epidemiology International Epidemiological Association 1997 Vol. 26, No. 5 Printed in Great Britain Change in Incidence of Crohn s Disease and Ulcerative Colitis in Denmark. A
Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth
Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes Dr. med. Henrik Csaba Horváth Why is risk stratification for colorectal cancer (CRC)
Health Service Development Manager (Specialist Nursing)
Health Service Development Manager (Specialist Nursing) Page 1 of 10 Health Service Development Manager (Specialist Nursing) Salary: Negotiable - dependant on experience Thank you for your interest in
Crohn's disease and pregnancy.
Gut, 1984, 25, 52-56 Crohn's disease and pregnancy. R KHOSLA, C P WILLOUGHBY, AND D P JEWELL From the Gastroenterology Unit, Radcliffe Infirmary, Oxford SUMMARY Infertility and the outcome of pregnancy
IBS TREATMENT CENTER
IBS TREATMENT CENTER NEWSLETTER JUNE 2010 IN THIS ISSUE 1...Treating Ulcerative Colitis and Crohn s Diseaase 2...Treating UC and Crohn s continued 2...Announcements 3...Annoucements 4...Dr. Wangen s Scheduled
INFLAMMATORY BOWEL DISEASE
INFLAMMATORY BOWEL DISEASE Update for Advanced Practice Clinicians and Allied Health Professionals Join Us... Friday, April 24, 2015 University Conference Center Penn State Milton S. Hershey Medical Center
MY CROHN S AND COLITIS CARE YOUR GUIDE
MY CROHN S AND COLITIS CARE YOUR GUIDE Sometimes living with IBD is frustrating but having the right information and support has helped me to feel more in control of my life. Melissa, 44 Diagnosed with
2. FRAGESTELLUNGEN DER VORGESTELLTEN ARBEITEN 26. 3.1 Wirksamkeit der Akupunktur bei ausgewählten Schmerzerkrankungen
2. FRAGESTELLUNGEN DER VORGESTELLTEN ARBEITEN 26 3 RELEVANTE ORIGINALARBEITEN 3.1 Wirksamkeit der Akupunktur bei ausgewählten Schmerzerkrankungen Brinkhaus B, Becker-Witt C, Jena S, Linde K, Streng A,
Pediatric Gastroenterology Fellowship Pediatric Nutrition Rotation Goals and Objectives - 1 st Year
Pediatric Nutrition Rotation Goals and Objectives - 1 st Year Goal 1: Gain experience and competency in managing common and rare gastrointestinal, liver and nutritional problems. (Competencies: patient
Midterm Final US S E NA 0 1 2 3 4 5. 8. Applies principles of epidemiology and demography in clinical practice.
Indiana University-Purdue University Fort Wayne College of Health and Human Services Department of Nursing Clinical Evaluation Form: Nurse Practitioner Graduate Program Student Name: Preceptor Name: Semester
EVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze
EVIDENCE BASED TREATMENT OF CROHN S DISEASE Dr E Ndabaneze PLAN 1. Case presentation 2. Topic on Evidence based Treatment of Crohn s disease - Introduction pathology aetiology - Treatment - concept of
An Overview of the Management of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) Sue Surgenor October 6 th 2015
An Overview of the Management of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) Sue Surgenor October 6 th 2015 Background Teasing out the differential Reviewing treatment options Personalised
Adult Inflammatory Bowel Disease Physician Performance Measures Set. August 2011*
Adult Inflammatory Bowel Disease Physician Performance Measures Set August 2011* *Last revised on October 26, 2011 American Gastroenterological Association Adult Inflammatory Bowel Disease Physician Performance
Establishment of a Population based Registry of Inflammatory Bowel Diseases in Fars Province, Iran
Original Article 97 Establishment of a Population based Registry of Inflammatory Bowel Diseases in Fars Province, Iran Seyed Alireza Taghavi 1, Kamran Bagheri Lankarani 2, Maryam Moini 1, Laleh Hamidpour
Original Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
Diabetes care in the Netherlands Providers perspective
in the Netherlands Providers perspective Care-standards Euro Consumer Diabetes Index 2008 1. Denmark (837 points out of 1000) 2. UK (836 points). 3. France (814) 4. The Netherlands (813) 5. Belgium (803)
Connect4 Patients CCCM Primary Care Community. Presented By: Veronica Mansfield, DNP, APRN, AE-C, CCM Kit McKinnon, MBA, BSN, RN, CDE, CCM
Connect4 Patients CCCM Primary Care Community Presented By: Veronica Mansfield, DNP, APRN, AE-C, CCM Kit McKinnon, MBA, BSN, RN, CDE, CCM September 17, 2015 Objectives: Describe innovative care management
John I Allen, MD, MBA
Specialty Clinical Service Lines John I Allen, MD, MBA Minnesota Gastroenterology American Gastroenterological Association ICSI Accountable Care Organization Primary Care Specialty Care Outpatient Care
REVIEW. Am J Gastroenterol advance online publication, 2 November 2010; doi:10.1038/ajg.2010.392
nature publishing group CLINICAL AND SYSTEMATIC S 1 The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn s and Colitis Organization:
Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy
Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy R Adams 1, Ct Ng 2, A Gibbs 2, L Tilson 1, D Veale 2, B Bresnihan 2, O FitzGerald 2, M Barry 1 1. National Centre for
2014 2015 Pre-Budget Consultation Submission to the Standing Committee on Finance. August 6 th, 2014
2014 2015 Pre-Budget Consultation Submission to the Standing Committee on Finance Executive Summary and Recommendations August 6 th, 2014 Crohn s and Colitis Canada is pleased to provide input to the Standing
Ulcerative Colitis & Proctitis. About Ulcerative Colitis & Proctitis
Ulcerative Colitis & Proctitis About Ulcerative Colitis & Proctitis When you first learn that you have ulcerative colitis, you will probably feel overwhelmed. You may not even have heard of ulcerative
Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
This fact sheet was adapted from www.cancerinsurancechecklist.org
IBD Insurance Checklist How This Checklist Can Help You The IBD Insurance Checklist is designed to help you compare insurance plans and consider your health needs when shopping for insurance in the Health
Call for Expressions of Interest
Call for Expressions of Interest Arla Foods Dairy Health and Nutrition Excellence Center Arla Foods, Sønderhøj 10, 8260 Viby J - E-mail: hejan@arlafoods.com Phone: 2095 1241 September 2015 2016 Call Introduction
Microscopic Colitis: Collagenous Colitis and Lymphocytic Colitis
Microscopic Colitis: Collagenous Colitis and Lymphocytic Colitis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is
Gut Decisions. Leading change to improve the lives of people with Crohn s and colitis
Gut Decisions Leading change to improve the lives of people with Crohn s and colitis Simon, an Irish Inflammatory Bowel Disease (IBD) patient, photographed at Kilmainham Jail as part of the Perspectives
Positive Coping with Rheumatoid Arthritis a skills workshop
Positive Coping with Rheumatoid Arthritis a skills workshop About this workshop Created by: Dan Bilsker PhD Centre for Applied Research in Mental Health & Addiction Faculty of Health Sciences, Simon Fraser
www.ijramr.com International Journal of Recent Advances in Multidisciplinary Research Vol. 02, Issue 12, pp.1016-1022, December, 2015
sz www.ijramr.com International Journal of Recent Advances in Multidisciplinary Research Vol. 02, Issue 12, pp.1016-1022, December, 2015 RESEARCH ARTICLE EVALUATION OF VALIDITY OF ULCERATIVE COLITIS ENDOSCOPIC
Informatics: Opportunities & Applications. Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit
Informatics: Opportunities & Applications Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit Routine Data "routine data" is data collected as byproducts of clinical
Addiction Billing. Kimber Debelak, CMC, CMOM, CMIS Director, Recovery Pathways
Addiction Billing Kimber Debelak, CMC, CMOM, CMIS Director, Recovery Pathways Objectives Provide overview of addiction billing contrasting E&M vs. behavioral health codes Present system changes in ICD-9
Optimizing Treatment Strategies in the Management of Inflammatory Bowel Disease ( IBD )
Inflammatory Bowel Disease Center Optimizing Treatment Strategies in the Management of Inflammatory Bowel Disease ( IBD ) Russell D. Cohen, M.D. F.A.C.G. A.G.A.F. Professor of Medicine, Pritzker Medical
INFLAMMATORY BOWEL DISEASE (IBD) MEASURES GROUP OVERVIEW
SPECIFICATION F MEASURES GROUP REPTING ONLY INFLAMMATY BOWEL DISEASE (IBD) MEASURES GROUP OVERVIEW 2012 PHYSICIAN QUALITY REPTING OPTIONS F MEASURES GROUPS: REGISTRY ONLY 2012 PHYSICIAN QUALITY REPTING
GENOTYPE AND PHENOTYPE, PREGNANCY AND DISEASE COURSE A European cohort study of IBD patients
GENOTYPE AND PHENOTYPE, PREGNANCY AND DISEASE COURSE A European cohort study of IBD patients 2006 PH.D. THESIS Lene Buhl Riis GENOTYPE AND PHENOTYPE, PREGNANCY AND DISEASE COURSE. A European cohort study
The Future Master in Nursing Science
The Future Master in Nursing Science by Lis Wagner & Birthe D. Pedersen 8th Why a demand for new academic qualifications? A new generation new users demands and expectations. Longevity among older people.
Biologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
August 13, 2013 15:35 WSPC/INSTRUCTION FILE gidatacentre. Multi-Datacenter Network of Knowledge Extraction and Dissemination for IBD Clinics
International Journal of Software Engineering and Knowledge Engineering c World Scientific Publishing Company Multi-Datacenter Network of Knowledge Extraction and Dissemination for IBD Clinics Kamran Sartipi
Estonian experience in teaching Motivational Interviewing for medical providers
Estonian experience in teaching Motivational Interviewing for medical providers Anneli Rätsep PhD GP senior researcher Department of Family Medicine University of Tartu Doctor s expectations that patient...
IBD Standards 2013 Update
Standards for the Healthcare of People who have Inflammatory Bowel Disease (IBD) IBD Standards 2013 Update The IBD Standards Group Association of Coloproctology of Great Britain and Ireland British Dietetic
Director of Income Generation. Appointment Briefing July 2014
Director of Income Generation Appointment Briefing July 2014 An introduction from the Chief Executive Thank you for your interest in joining the team at Crohn s and Colitis UK. We are currently entering
PATRICK HANAWAY, M.D.
63 Zillicoa Street Asheville, NC 28801 (828) 210-7400 Employment GENOVA DIAGNOSTICS 2002-2007 Chief Medical Officer, Vice President 1 st Medical Director of Great Smokies Diagnostic Lab, now with oversight
Media Release. Basel, 11 June 2009. RA patients with enhanced response identified
Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
Henriëtte van der Horst VUmc Head of Department of General Practice and Elderly Care Medicine
MUS and psychiatry in primary care Henriëtte van der Horst VUmc Head of Department of General Practice and Elderly Care Medicine Double Dutch: two topics Major changes in the mental health care organisation
I. Should All New Brunswickers be required to have drug coverage?
Crohn's and Colitis Foundation of Canada Fondation canadlenne des maladies Inflarnmatolres de l'lntestin 600-60 St. Clair Avenue East Toronto, ON Canada M4T INS Tel: (116) 'no.sols Fax: (416) 'n9-0364
Diabetes care in the Netherlands
in the Netherlands Care-standards Structure of Workshop Short introduction: in the Netherlands 10min Discussion of 4 questions 60min How can self management be a part of diabetes disease management? How
QS114. NICE quality standard for irritable bowel syndrome in adults (QS114)
NICE quality standard for irritable bowel syndrome in adults (QS114) QS114 NICE approved the reproduction of its content for this booklet. The production of this booklet is sponsored by Thermo Fisher Scientific,
Trauma-Informed Care Innovation Community Webinar #4: Building Trusting Relationships through Safe Interactions and Peer Support
Presenters: Trauma-Informed Care Innovation Community Webinar #4: Building Trusting Relationships through Safe Interactions and Peer Support Linda Ligenza, LCSW, CIHS, National Council Beth Filson, CPS,
Victorian Nurse Practitioner Project Phase 4, Round 4.11 - Chronic Disease Management
Victorian Nurse Practitioner Project Phase 4, Round 4.11 - Chronic Disease Management Eastern Health Multiple Sclerosis Nurse Practitioner Service Model April 2014 Prepared by Jodi Haartsen and Deanna
Recovery and Dual Diagnosis
Recovery and Dual Diagnosis Martha Levey, Ed.D. Affiliated Service Providers of Indiana, Inc. The mission of ASPIN is to provide innovative educational programs, resource management, program development,
Characterisation of a Palliative Care Population in a Comprehensive Cancer Centre
Characterisation of a Palliative Care Population in a Comprehensive Cancer Centre Kirstine Skov Benthien, Mie Nordly, Katja Videbæk, Lisbeth Grave Bendixen, Louise Christoffersen, Hans von der Maase, Geana
Digestive and Liver Disease
Digestive and Liver Disease 43 (2011) 1 20 Contents lists available at ScienceDirect Digestive and Liver Disease journal homepage: www.elsevier.com/locate/dld Progress Report The Italian Society of Gastroenterology
Facilitating Behavior Change
Facilitating Behavior Change This section contains the following subjects: Readiness to Change Motivational Interviewing 57 ASSESSING AND INCREASING MOTIVATION Adherence and nonadherence are behaviors,
IBD: Ulcerative Colitis Monday, February 10, 2014 The Fairmont Royal York Toronto, ON
IBD: Ulcerative Colitis Monday, February 10, 2014 The Fairmont Royal York Toronto, ON Accreditation This event has been approved as an accredited (Section1) group learning activity as defined by the Maintenance
Workshop on Patient Support and Market Research Programmes
Workshop on Patient Support and Market Research Programmes Spectrum of programmes falling under the terms of PSP and MRPs and the and the type of safety data collected Pharmaceutical Industry Associations
Crohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals. Sponsored Research Program in Inflammatory Bowel Disease
Crohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals Sponsored Research Program in Inflammatory Bowel Disease Presentation Overview Background on inflammatory bowel disease Partner Overview
In vitro co-culture model of the inflamed intestinal mucosa
In vitro co-culture model of the inflamed intestinal mucosa Berlin, December 13, 2011 Eva-Maria Collnot, e.collnot@mx.uni-saarland.de Helmholtz Institute for Pharmaceutical Research Saarland Departement
Guidelines for the management of inflammatory bowel disease in adults
v1 GUIDELINES Guidelines for the management of inflammatory bowel disease in adults M J Carter, A J Lobo, S P L Travis, on behalf of the IBD Section of the British Society of Gastroenterology... Gut 2004;53(Suppl
WHAT TYPES OF PROGRAMMES ARE AVAILABLE?
SHOULD I APPLY? You do not have to apply immediately after your undergraduate work Graduate school is a HUGE commitment (so is the application process) Completion of a programme takes time (approximately
Antidepressant Skills @ Work Dealing with Mood Problems in the Workplace
Antidepressant Skills @ Work Dealing with Mood Problems in the Workplace Dr. Joti Samra PhD, R.Psych. Adjunct Professor & Research Scientist CARMHA www.carmha.ca Dr. Merv Gilbert PhD, R.Psych. Principal
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
TELEMEDICINE A KEY TO HEALTH SERVICES OF THE FUTURE
THE DANISH GOVERNMENT LOCAL GOVERNMENT DENMARK DANISH REGIONS AUGUST 2012 NATIONAL ACTION PLAN FOR DISSEMINATION OF TELEMEDICINE IN BRIEF TELEMEDICINE A KEY TO HEALTH SERVICES OF THE FUTURE TELEMEDICINE
Guide to Abdominal or Gastroenterological Surgery Claims
What are the steps towards abdominal surgery? Investigation and Diagnosis It is very important that all necessary tests are undertaken to investigate the patient s symptoms appropriately and an accurate
A PARENT S GUIDE. Caring for a Child with Crohn s or Colitis
A PARENT S GUIDE Caring for a Child with Crohn s or Colitis WHAT NOW? CROHN S & COLITIS: IBD not IBS Your child has been diagnosed with Crohn s disease or ulcerative colitis, or perhaps an indeterminate
P A T H W A Y S T O A. Career in. Sports Medicine
P A T H W A Y S T O A Career in Sports Medicine P A T H W A Y S T O A Career in Sports Medicine What is sports medicine? Sports medicine is not a single career, but instead a widely varied group of professionals
What Is Clostridium Difficile (C. Diff)? CLOSTRIDIUM DIFFICILE (C. DIFF)
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium, or bug, that can grow in your intestines and cause bad GI symptoms. The main risk
Overcoming Resistance to Stopping Tobacco Use: A Motivational Approach
Overcoming Resistance to Stopping Tobacco Use: A Motivational Approach Lowell C. Dale, MD Associate Professor of Medicine Mayo Clinic Nicotine Dependence Center & Division of Primary Care Internal Medicine
Assessment of depression in adults in primary care
Assessment of depression in adults in primary care Adapted from: Identification of Common Mental Disorders and Management of Depression in Primary care. New Zealand Guidelines Group 1 The questions and
1. THE VALUE OF USING SMARTPHONE APPS IN BUSINESS INTELLIGENCE TO ACCESS THE EXPERIENCING SELF
1. THE VALUE OF USING SMARTPHONE APPS IN BUSINESS INTELLIGENCE TO ACCESS THE EXPERIENCING SELF PAUL MANNU CELLO HEALTH INSIGHT 1 The rapid growth in smartphone usage offers healthcare market researchers
Patient Reported Outcome Data: Why PROs Will Be The Next Wave in Big Data. Neil B. Minkoff, M.D. Chief Medical Officer EmpiraMed
Patient Reported Outcome Data: Why PROs Will Be The Next Wave in Big Data Neil B. Minkoff, M.D. Chief Medical Officer EmpiraMed PRO Overview Presentation Proprietary & Confidential PRO Use and Barriers
Celiac Disease. Donald Schoch, M.D. Ohio ACP Meeting October 17, 2014
Celiac Disease Donald Schoch, M.D. Ohio ACP Meeting October 17, 2014 None to disclose Conflicts of Interest Format Present a case Do a pretest about the evaluation Review case Discuss the questions & answers
Rheumatoid Arthritis
A Self-determination theory based intervention to promote autonomous motivation for physical activity engagement among patients with Rheumatoid Arthritis Sally Fenton, PhD Research Fellow School of Sport,
Opportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD
Opportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD Raymond Cross, M.D., M.S., AGAF Associate Professor of Medicine Director of the Inflammatory Bowel Disease Program
HIV Outpatient Clinical Care Pathway Version 11 [As per 10 updated for documentation review]
![HIV Outpatient Clinical Care Pathway Version 11 [As per 10 updated for documentation review]](/thumbs/33/16158850.jpg "HIV Outpatient Clinical Care Pathway Version 11 [As per 10 updated for documentation review]")
HIV Outpatient Clinical Care Pathway Version 11 [As per 10 updated f documentation review] Categy 1: New Categy 2: Stable Categy 3: Complex - ACCESS HIV + Diagnosis Patient from: G.U. clinic A&E Medical